Good evening and welcome to Markets Desk, where we're cutting through the noise on the stories that matter.
Rivian is putting everything on the table with its R2, and early impressions suggest the bet may pay off. The sixty-one thousand four hundred eighty-five dollar Performance trim delivers serious speed alongside the brand's signature personality, though analysts watching Rivian's survival odds will note that lower-priced trims could be the real volume driver here.
Shifting to telecom, T-Mobile is feeling the friction from a string of pricing changes that appear to be testing customer patience. After cutting voice line discounts, trimming its five-year price guarantee, and raising rates on home internet plans, the carrier is now seeing loyalty metrics move in the wrong direction, a warning sign for a brand that built its identity on disrupting the status quo.
And in biotech, Isomorphic Labs, the Google DeepMind spinoff led by AI pioneer Demis Hassabis, is pushing hard into AI-driven drug discovery with an audacious claim from its president, Max Jaderberg, that within five years all drugs will be designed by artificial intelligence. The implications for oncology pipelines and pharmaceutical valuations are significant and worth watching closely.
That's the tape. Markets Desk, signing off the floor.
